Due to supply disruptions in the growth hormone market, the Pfizer Bridge Program is experiencing very high call volumes and increased demand for Genotropin pen devices. Long hold times are possible on the phone and patients may have to wait to receive a Genotropin pen. Pfizer does not foresee any long-term supply disruption and we are working to resolve the situation as quickly as possible.
